低分子イノベーターAPI CDMO 市場規模、シェア、動向分析レポート：ステージタイプ別、顧客タイプ別、治療領域別、地域別、セグメント別予測、2025年～2030年

低分子イノベーターAPI CDMO市場の成長と動向

Grand View Research, Inc.の最新レポートによると、低分子イノベーターAPI CDMOの世界市場規模は2030年までに471億4,000万米ドルに達し、2025～2030年のCAGRは6.38％を記録すると予測されています。

製薬企業のアウトソーシング傾向の高まり、低分子医薬品の需要増加、臨床検査件数の急増が市場にプラスの影響を与えると予測されています。製薬セクターにおけるCDMOの利用拡大には様々な理由があり、中でも費用対効果が顕著な要因となっています。アウトソーシングは、高価なインフラや設備投資の必要性を回避して経費を削減する製薬会社の効率的な戦略として浮上しています。CDMOは、必要な専門知識とインフラを提供し、財務的に賢明な方法で医薬品開発と製造サービスを記載しています。

さらに、効率性の向上も医薬品アウトソーシングの重要な推進力となっています。新薬の市場導入を急がなければならないという製薬会社のプレッシャーが高まる中、アウトソーシングは医薬品開発プロセスを加速させるソリューションとして浮上しています。CDMOは、その専門知識、経験、最先端の設備を活用し、高品質な医薬品の迅速かつ効率的な生産を促進し、製薬企業が開発スケジュールを遵守することを可能にします。加えて、新規治療や希少疾病用医薬品の流入が増加していることや、承認済み製品の収益率が高いことから、先進的なインフラや専門知識を利用するためにCDMOを選択する製薬企業もあります。さらに、CDMOの継続的な技術進歩は、医療産業における技術革新、効率性、規制遵守への高まる要求に応える革新的な低分子原薬を提供しています。

企業が先端技術を採用することで、医薬品開発、製造プロセス、生産性が向上します。製薬産業における新規低分子イノベーターAPIに対する需要の増加は、商業CDMOの能力拡大を促しており、これが市場成長を押し上げると予想されます。例えば、2023年8月、アステックスはMSDとの間で、がん治療用の腫瘍抑制タンパク質を持つ低分子化合物候補を分類するための共同研究＆ライセンス契約を発表しました。この契約に基づき、同社はフラグメントベースの創薬プラットフォームを用いて化合物を開発し、前臨床開発・最適化のための主要化合物をMSDに記載しています。

低分子イノベーターAPI CDMO市場レポートハイライト

• 臨床ステージタイプセグメントは低分子イノベーターAPI CDMO産業をリードし、2024年の世界収益の54.56%を占めました。前臨床セグメントは予測期間中に有利なCAGRで成長すると予測されています。
• 医薬品セグメントは2024年の市場を独占し、91.07%の収益シェアを占めました。低分子医薬品は、ほぼ1世紀にわたって製薬産業の屋台骨を支えてきました。バイオテクノロジーセグメントの拡大は、バイオテクノロジーに対する需要の高まりと分子効率の向上が原動力となっています。
• 2024年の低分子イノベーターAPI CDMO市場は、オンコロジーセグメントが支配的であり、予測期間中のCAGRは6.80%と最速で成長する見込みです。感染症市場は、様々な疾患セグメントでダイナミックな動向とシナリオを確認しています。
• 北米の低分子イノベーターAPI CDMO市場は予測期間中CAGR 5.91%で成長する見込みです。アジア太平洋は2024年に41.74%の最大市場シェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 低分子イノベーターAPI CDMO市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/補助市場展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 技術
  • 低分子イノベーターAPI CDMO市場へのAIの統合
• 相別・地域別臨床検査総数（2021～2024年）
  • 相別臨床検査総数（2021～2024年）
  • 地域別臨床検査総数（2021～2024年）
• 価格モデル分析
• 市場分析ツール
  • ポーターの5つの分析
  • SWOT分析によるPESTEL
  • COVID-19の影響分析

第4章 低分子イノベーターAPI CDMO市場：ステージタイプ別、推定・動向分析

• 低分子イノベーターAPI CDMO市場、ステージタイプ別：セグメントダッシュボード
• 低分子イノベーターAPI CDMO市場、ステージタイプ別：変動分析
• ステージタイプ別、2018～2030年
• 前臨床
• 臨床
  • フェーズI
  • フェーズII
  • フェーズIII
• 商用

第5章 低分子イノベーターAPI CDMO市場：顧客タイプ別、推定・動向分析

• 低分子イノベーターAPI CDMO市場、顧客タイプ別：セグメントダッシュボード
• 低分子イノベーターAPI CDMO市場、顧客タイプ別：変動分析
• 顧客タイプ別、2018～2030年
• 医薬品
  • 小
  • 中
  • 大
• バイオテクノロジー
  • 小
  • 中
  • 大

第6章 低分子イノベーターAPI CDMO市場：治療領域別、推定・動向分析

• 低分子イノベーターAPI CDMO市場、治療領域別：セグメントダッシュボード
• 低分子イノベーターAPI CDMO市場、治療領域別：変動分析
• 治療領域別、2018～2030年
• 心血管疾患
• 腫瘍学
• 呼吸器疾患
• 神経学
• 代謝障害
• 感染症
• その他

第7章 低分子イノベーターAPI CDMO市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 世界地域市場のスナップショット
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国
  • タイ
  • 台湾
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート
  • イスラエル

第8章 競合情勢

• 市場参入企業の分類
• 市況分析、2024年（ヒートマップ分析）
• 企業プロファイル
  • Lonza Group Ltd.
  • Novo Holdings（Catalent, Inc.）
  • Thermo Fisher Scientific, Inc.
  • Siegfried Holding AG
  • Recipharm AB
  • CordenPharma International
  • Samsung Biologics
  • Labcorp
  • Ajinomoto Bio-Pharma Services
  • Piramal Pharma Solutions
  • Jubilant Life Sciences（Jubilant Biosys Limited）
  • WuXi AppTec Co., Ltd.

List of Tables

• Table 1 List of Tables
• Table 2 List of Secondary Sources
• Table 3 List of Abbreviations
• Table 4 Global Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 5 Global Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 6 Global Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 7 Global Small Molecule Innovator API CDMO Market, by Region, 2018 - 2030 (USD Million)
• Table 8 North America Small Molecule Innovator API CDMO Market, by Country, 2018 - 2030 (USD Million)
• Table 9 North America Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 10 North America Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 11 North America Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 12 U.S. Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 13 U.S. Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 14 U.S. Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 15 Canada Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 16 Canada Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 17 Canada Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 18 Mexico Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 19 Mexico Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 20 Mexico Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 21 Europe Small Molecule Innovator API CDMO Market, by Country, 2018 - 2030 (USD Million)
• Table 22 Europe Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 23 Europe Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 24 Europe Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 25 UK Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 26 UK Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 27 UK Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 28 Germany Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 29 Germany Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 30 Germany Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 31 France Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 32 France Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 33 France Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 34 Italy Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 35 Italy Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 36 Italy Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 37 Spain Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 38 Spain Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 39 Spain Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 40 Denmark Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 41 Denmark Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 42 Denmark Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 43 Sweden Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 44 Sweden Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 45 Sweden Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 46 Norway Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 47 Norway Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 48 Norway Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Small Molecule Innovator API CDMO Market, by Country, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 51 Asia Pacific Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 52 Asia Pacific Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 53 China Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 54 China Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 55 China Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 56 Japan Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 57 Japan Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 58 Japan Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 59 India Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 60 India Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 61 India Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 62 Australia Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 63 Australia Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 64 Australia Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 65 South Korea Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 66 South Korea Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 67 South Korea Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 68 Thailand Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 69 Thailand Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 70 Thailand Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 71 Taiwan Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 72 Taiwan Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 73 Taiwan Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 74 Latin America Small Molecule Innovator API CDMO Market, by Country, 2018 - 2030 (USD Million)
• Table 75 Latin America Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 76 Latin America Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 77 Latin America Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 78 Brazil Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 79 Brazil Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 80 Brazil Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 81 Argentina Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 82 Argentina Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 83 Argentina Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 84 Middle East & Africa Small Molecule Innovator API CDMO Market, by Country, 2018 - 2030 (USD Million)
• Table 85 Middle East & Africa Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 86 Middle East & Africa Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 87 Middle East & Africa Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 88 South Africa Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 89 South Africa Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 90 South Africa Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 91 Saudi Arabia Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 92 Saudi Arabia Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 93 Saudi Arabia Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 94 UAE Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 95 UAE Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 96 UAE Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 97 Kuwait Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 98 Kuwait Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 99 Kuwait Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 100 Israel Small Molecule Innovator API CDMO Market, by Stage Type, 2018 - 2030 (USD Million)
• Table 101 Israel Small Molecule Innovator API CDMO Market, by Customer Type, 2018 - 2030 (USD Million)
• Table 102 Israel Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Small molecule innovator API CDMO market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Market formulation & validation
• Fig. 7 Commodity flow analysis
• Fig. 8 Value-Chain-Based Sizing & Forecasting
• Fig. 9 QFD model sizing & forecasting
• Fig. 10 Bottom-up approach
• Fig. 11 Market snapshot
• Fig. 12 Segment snapshot 1
• Fig. 13 Segment snapshot 2
• Fig. 14 Competitive landscape snapshot
• Fig. 15 Parent market outlook, 2024 (USD Million)
• Fig. 16 Ancillary market outlook, 2024 (USD Million)
• Fig. 17 Small Molecule Innovator API CDMO Market Dynamics
• Fig. 18 Percentage of clinical trials by major countries in North America
• Fig. 19 Percentage of clinical trials by major countries in Europe
• Fig. 20 Percentage of clinical trials by major countries in Asia Pacific
• Fig. 21 Percentage of clinical trials by major countries in Latin America
• Fig. 22 Percentage of clinical trials by major countries in Middle East & Africa
• Fig. 23 Porter's five forces analysis
• Fig. 24 Small molecule innovator API CDMO market: PESTEL analysis
• Fig. 25 Small Molecule Innovator API CDMO Market: Stage Type outlook and key takeaways
• Fig. 26 Small Molecule Innovator API CDMO Market: Stage Type movement analysis
• Fig. 27 Preclinical market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Clinical market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Phase I market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Phase II market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Phase III market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Commercial market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Small Molecule Innovator API CDMO Market: Customer Type outlook and key takeaways
• Fig. 34 Small Molecule Innovator API CDMO Market: Customer Type movement analysis
• Fig. 35 Pharmaceutical market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Small market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Medium market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Large market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 Biotechnology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Small market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 41 Medium market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 42 Large market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 43 Small Molecule Innovator API CDMO Market: Therapeutic Area outlook and key takeaways
• Fig. 44 Small Molecule Innovator API CDMO Market: Therapeutic Area movement analysis
• Fig. 45 Cardiovascular Diseases market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 46 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 47 Respiratory Disorders market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 48 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 49 Metabolic Disorders market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 50 Infectious Diseases market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 51 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 52 Regional Marketplace: Key Takeaways
• Fig. 53 North America Small Molecule Innovator API CDMO Market estimates and forecasts, 2018-2030 (USD Million)
• Fig. 54 Key country dynamics
• Fig. 55 U.S. Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Key country dynamics
• Fig. 57 Canada Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Key country dynamics
• Fig. 59 Mexico Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Europe Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Key country dynamics
• Fig. 62 UK Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Key country dynamics
• Fig. 64 Germany Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Key country dynamics
• Fig. 66 France Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Key country dynamics
• Fig. 68 Italy Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Key country dynamics
• Fig. 70 Spain Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Key country dynamics
• Fig. 72 Denmark outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Key country dynamics
• Fig. 74 Sweden outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Key country dynamics
• Fig. 76 Norway outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Asia Pacific Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Key country dynamics
• Fig. 79 China Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Key country dynamics
• Fig. 81 Japan Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Key country dynamics
• Fig. 83 India Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Key country dynamics
• Fig. 85 Australia Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Key country dynamics
• Fig. 87 South Korea Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Key country dynamics
• Fig. 89 Thailand Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Key country dynamics
• Fig. 91 Taiwan Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Latin America Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 93 Key country dynamics
• Fig. 94 Brazil Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 95 Key country dynamics
• Fig. 96 Argentina Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 97 MEA Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 98 Key country dynamics
• Fig. 99 South Africa Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 100 Fig. Key country dynamics
• Fig. 101 Saudi Arabia Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 102 Key country dynamics
• Fig. 103 UAE Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 104 Key country dynamics
• Fig. 105 Kuwait Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 106 Key country dynamics
• Fig. 107 Israel Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 108 Key company categorization
• Fig. 109 Service heat map analysis
• Fig. 110 Strategic framework

Small Molecule Innovator API CDMO Market Growth & Trends:

The global small molecule innovator API CDMO market size is expected to reach USD 47.14 billion by 2030, registering a CAGR of 6.38% from 2025 to 2030, according to a new report by Grand View Research, Inc. A growing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and a surge in the number of clinical trials are anticipated to influence the market positively. The growing utilization of CDMOs in the pharmaceutical sector stems from various reasons, with cost-effectiveness as the prominent factor. Outsourcing emerges as an efficient strategy for pharmaceutical firms to reduce expenses by sidestepping the necessity for costly infrastructure and equipment investments. CDMOs offer the requisite expertise and infrastructure to deliver drug development and manufacturing services in a financially prudent manner.

Furthermore, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules. In addition, several pharmaceutical companies prefer CDMOs to access advanced infrastructure and expertise due to the increasing influx of novel therapies & orphan drugs and higher returns on approved products. Moreover, continuous technological advancements among CDMOs offer innovative small molecule APIs to meet the growing demands for innovation, efficiency, and regulatory compliance in the healthcare industry.

The adoption of advanced technologies by companies enhances drug development, manufacturing processes, and productivity. The increasing demand for new small molecule innovator API in the pharmaceutical industry is encouraging commercial CDMOs to expand their capabilities, which is expected to boost market growth. For instance, in August 2023, Astex announced a research collaboration & license agreement with MSD to classify small molecule candidates with tumor suppressor proteins for cancer treatment. Under the agreement, the company will use its fragment-based drug discovery platform to develop compounds and provide MSD with main compounds for preclinical development & optimization.

Small Molecule Innovator API CDMO Market Report Highlights:

• The clinical stage type segment led the small molecule innovator API CDMO industry and accounted for 54.56% of global revenue in 2024. The preclinical segment is anticipated to grow at a lucrative CAGR over the forecast period.
• The pharmaceutical segment dominated the market in 2024, accounting for a revenue share of 91.07%. Small-molecule drugs have been the backbone of the pharmaceutical industry for nearly a century. The biotechnology segment's expansion is driven by rising demand for biotechnology and enhanced molecular efficiency.
• The oncology segment dominated the small molecule innovator API CDMO market in 2024 and is expected to grow at the fastest CAGR of 6.80% during the forecast period. The infectious diseases market has witnessed dynamic trends and scenarios across various disease segments.
• North America small molecule innovator API CDMO market is expected to grow at a CAGR of 5.91% over the forecast period. Asia Pacific held the largest market share of 41.74% in 2024.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Stage Type
  • 1.2.2. Customer Type
  • 1.2.3. Therapeutic Area
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Parent Market Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Small Molecule Innovator API CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Demand for Small Molecule Drugs
    • 3.2.1.2. Increasing Outsourcing Trends Among Pharmaceutical Companies
    • 3.2.1.3. Surge In Number of Clinical Trials
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Compliance Issues While Outsourcing
    • 3.2.2.2. Changing Scenarios in Developing Economies
• 3.3. Technological Landscape
  • 3.3.1. Integration of AI in Small Molecule Innovator API CDMO Market
    • 3.3.1.1. Current Dynamics and Future Trends
      • 3.3.1.1.1. Drug Discovery and Design
      • 3.3.1.1.2. AI-Assisted Drug API Synthesis
      • 3.3.1.1.3. Process Optimization
      • 3.3.1.1.4. Supply Chain Management
      • 3.3.1.1.5. Clinical Trial Optimization
      • 3.3.1.1.6. Regulatory Compliance
• 3.4. Total Number of Clinical Trials by Phase & Region (2021 - 2024)
  • 3.4.1. Total Number of Clinical Trials by Phase (2021 - 2024)
  • 3.4.2. Total Number of Clinical Trials by Region (2021 - 2024)
    • 3.4.2.1. Percentage of Clinical Trials by Major Countries in North America:
    • 3.4.2.2. Percentage of Clinical Trials by Major Countries in Europe:
    • 3.4.2.3. Percentage of Clinical Trials by Major Countries in Asia Pacific:
    • 3.4.2.4. Percentage of Clinical Trials by Major Countries in Latin America:
    • 3.4.2.5. Percentage of Clinical Trials by Major Countries in the Middle East & Africa:
    • 3.4.2.6. Total Number of Clinical Trials by Therapeutic Area (2021 - 2024)
• 3.5. Pricing Model Analysis
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Analysis
  • 3.6.2. PESTEL by SWOT Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis

• 4.1. Small Molecule Innovator API CDMO Market, By Stage Type: Segment Dashboard
• 4.2. Small Molecule Innovator API CDMO Market, By Stage Type: Movement Analysis
• 4.3. Small Molecule Innovator API CDMO Market Estimates & Forecasts, By Stage Type, 2018 - 2030
• 4.4. Preclinical
  • 4.4.1. Preclinical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Clinical
  • 4.5.1. Clinical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Phase I
    • 4.5.2.1. Phase I Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Phase II
    • 4.5.3.1. Phase II Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Phase III
    • 4.5.4.1. Phase III Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Commercial
  • 4.6.1. Commercial Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis

• 5.1. Small Molecule Innovator API CDMO Market, By Customer Type: Segment Dashboard
• 5.2. Small Molecule Innovator API CDMO Market, By Customer Type: Movement Analysis
• 5.3. Small Molecule Innovator API CDMO Market Estimates & Forecasts, By Customer Type, 2018 - 2030
• 5.4. Pharmaceutical
  • 5.4.1. Pharmaceutical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Small
    • 5.4.2.1. Small Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Medium
    • 5.4.3.1. Medium Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Large
    • 5.4.4.1. Large Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Biotechnology
  • 5.5.1. Biotechnology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.2. Small
    • 5.5.2.1. Small Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Medium
    • 5.5.3.1. Medium Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.4. Large
    • 5.5.4.1. Large Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Small Molecule Innovator API CDMO Market, By Therapeutic Area: Segment Dashboard
• 6.2. Small Molecule Innovator API CDMO Market, By Therapeutic Area: Movement Analysis
• 6.3. Small Molecule Innovator API CDMO Market Estimates & Forecasts, By Therapeutic Area, 2018 - 2030
• 6.4. Cardiovascular Diseases
  • 6.4.1. Cardiovascular Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Oncology
  • 6.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Respiratory Disorders
  • 6.6.1. Respiratory Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Neurology
  • 6.7.1. Neurology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Metabolic Disorders
  • 6.8.1. Metabolic Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.9. Infectious Diseases
  • 6.9.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.10. Others
  • 6.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Small Molecule Innovator API CDMO Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. North America
  • 7.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. U.S
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. Japan
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.8. Taiwan
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Competitive Scenario
    • 7.6.8.3. Regulatory Framework
    • 7.6.8.4. Taiwan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.6. Israel
    • 7.8.6.1. Key Country Dynamics
    • 7.8.6.2. Competitive Scenario
    • 7.8.6.3. Regulatory Framework
    • 7.8.6.4. Israel Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Market Position Analysis, 2024 (Heat Map Analysis)
• 8.3. Company Profiles
  • 8.3.1. Lonza Group Ltd.
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Novo Holdings (Catalent, Inc.)
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Thermo Fisher Scientific, Inc.
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Siegfried Holding AG
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Recipharm AB
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. CordenPharma International
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Samsung Biologics
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Labcorp
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Ajinomoto Bio-Pharma Services
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Piramal Pharma Solutions
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. Jubilant Life Sciences (Jubilant Biosys Limited)
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Service Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. WuXi AppTec Co., Ltd.
    • 8.3.12.1. Company Overview
    • 8.3.12.2. Financial Performance
    • 8.3.12.3. Service Benchmarking
    • 8.3.12.4. Strategic Initiatives